Parosteal osteosarcoma with myocardial metastasis 13 years after follow-up

PURPOSE: To report the case of a woman with a diagnosis of grade II (low grade) parosteal osteosarcoma with the occurrence of myocardial metastasis 13 years after resection, and to present a review of the existing literature on the subject. METHODS: Description of the case and review of the literature. CONCLUSION: The review leads to the conclusion that the occurrence of metastasis from parosteal osteosarcoma can occur in up to 38% of the cases, in spite of its relatively low aggressiveness. However, myocardial metastasis of a parosteal osteosarcoma is an event that was not found in the literature.

Lipoma parosteal de arco costal: relato de caso

Os autores relatam o caso de um paciente com história de tumoração na região subaxilar esquerda, de crescimento progressivo, com início há vários anos. A radiografia e a tomografia computadorizada evidenciaram lesão expansiva com densidade menor do que partes moles adjacentes, com contornos bem definidos, contígua ao quinto arco costal esquerdo, com ossificações irregulares em seu interior. Histologicamente, foi diagnosticado lipoma parosteal, um raro tumor benigno de crescimento lento.

Osteossarcoma parosteal: aspectos na radiologia convencional

OBJETIVO: Avaliar os achados clínicos mais importantes do osteossarcoma parosteal e descrever os seus aspectos mais comuns na radiologia convencional. MATERIAIS E MÉTODOS: Estudo retrospectivo com 26 pacientes com osteossarcoma parosteal, provenientes do arquivo do Clube do Osso, Rio de Janeiro, RJ, e análise dos principais achados clínicos e aspectos radiológicos. RESULTADOS: A doença predominou em pacientes do sexo feminino e teve idade média de acometimento na terceira década de vida. Os achados clínicos mais freqüentes foram o aumento do volume no local do tumor (77% dos casos) e a dor local (68% dos casos). O local mais comum de tumor foi o oco poplíteo, com 40% dos casos, e houve envolvimento metafisário em 92% dos tumores. O aspecto radiológico mais comumente encontrado foi de lesão bem mineralizada e intimamente justaposta à superfície óssea, com o córtex adjacente irregularmente espessado (92,3% dos casos), observando-se área de adesão a este (88,5% dos casos), além de margens tumorais lobuladas (50% dos casos) ou irregulares (38,5% dos casos). Evidenciaram-se, também, linha radiolucente entre o tumor e o osso adjacente (48% dos casos), padrão de mineralização mais denso na base do que na periferia (42,3% dos casos) e pequena ocorrência de reação periosteal (15,4% dos casos). CONCLUSÃO: Apesar de a tomografia computadorizada e a ressonância magnética serem importantes na identificação de alguns aspectos do osteossarcoma parosteal, a radiologia convencional é altamente sugestiva deste tumor e permite, na maior parte dos casos, o diagnóstico diferencial com outras lesões da superfície óssea.

MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.

Low-grade osteosarcoma is a rare malignancy that may be subdivided into two main subgroups on the basis of location in relation to the bone cortex, that is, parosteal osteosarcoma and low-grade central osteosarcoma. Their histological appearance is quite similar and characterized by spindle cell stroma with low-to-moderate cellularity and well-differentiated anastomosing bone trabeculae. Low-grade osteosarcomas have a simple genetic profile with supernumerary ring chromosomes comprising amplification of chromosome 12q13-15, including the cyclin-dependent kinase 4 (CDK4) and murine double-minute type 2 (MDM2) gene region. Low-grade osteosarcoma can be confused with fibrous and fibro-osseous lesions such as fibromatosis and fibrous dysplasia on radiological and histological findings. We investigated MDM2-CDK4 immunohistochemical expression in a series of 72 low-grade osteosarcomas and 107 fibrous or fibro-osseous lesions of the bone or paraosseous soft tissue. The MDM2-CDK4 amplification status of low-grade osteosarcoma was also evaluated by comparative genomic hybridization array in 18 cases, and the MDM2 amplification status was evaluated by fluorescence in situ hybridization or quantitative real-time polymerase chain reaction in 31 cases of benign fibrous and fibro-osseous lesions. MDM2-CDK4 immunostaining and MDM2 amplification by fluorescence in situ hybridization or quantitative real-time polymerase chain reaction were investigated in a control group of 23 cases of primary high-grade bone sarcoma, including 20 conventional high-grade osteosarcomas, two pleomorphic spindle cell sarcomas/malignant fibrous histiocytomas and one leiomyosarcoma. The results showed that MDM2 and/or CDK4 immunoreactivity was present in 89% of low-grade osteosarcoma specimens. All benign fibrous and fibro-osseous lesions and the tumors of the control group were negative for MDM2 and CDK4. These results were consistent with the MDM2 and CDK4 amplification results. In conclusion, immunohistochemical expression of MDM2 and CDK4 is specific and provides sensitive markers for the diagnosis of low-grade osteosarcomas, helping to differentiate them from benign fibrous and fibro-osseous lesions, particularly in cases with atypical radio-clinical presentation and/or limited biopsy samples.